Skip to main content


Browse the latest news, expert commentary, and educational content on hyperglycemia.


Close up of doctor explaining treatment methods to patient

05-12-2022 | SGLT2 inhibitors | News

Algorithm could optimize SGLT2 vs DPP-4 inhibitor decisions in clinical practice

An algorithm based on real-world clinical data could support decisions between use of SGLT2 inhibitors and DPP-4 inhibitors in people with type 2 diabetes.

Syringe and pills

01-11-2022 | SGLT2 inhibitors | News

Real-world adjunctive medication outcomes in type 1 diabetes revealed

People with type 1 diabetes who take GLP-1 receptor agonists or SGLT2 inhibitors in clinical practice have outcomes that are mostly – but not all – in line with those in controlled trials, say researchers.

Healthy breakfast - symbolic image with model

21-07-2022 | Sotagliflozin | News

Sotagliflozin effects differ from empagliflozin only at breakfast

The only notable short-term differences in the effects of sotagliflozin and empagliflozin occur in glucose metabolism after breakfast, show findings from a randomized trial.

Featured contributor

Simon Heller is Professor of Clinical Diabetes at the University of Sheffield, Director of Research and Development and Honorary Consultant Physician at Sheffield Teaching Hospitals Foundation Trust, UK. 

In this featured article, Prof. Heller explains why time-in-range targets are so helpful for people with diabetes… yet handing out continuous glucose monitoring devices willy-nilly could do more harm than good.

Read the article